Addressing of Efficacy and Safety of Femtosecond-laser Assisted Versus Manual Lens Fragmentation Procedure

Cataract Clinical Trial

Official title:

A Multi-centre, Multi-surgeon, Randomized, Controlled, Prospective, Post-Market-Clinical-Follow-Up Study to Investigate the Impact of Cataract Grade on the Efficacy and Safety of Femtosecond-laser Assisted Lens Fragmentation Procedure

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01971177
• Other study ID #: 1304
• Status: Completed
• Phase: Phase 4
• First received: October 23, 2013
• Last updated: March 13, 2014
• Start date: October 2013
• Est. completion date: February 2014

Study information

• Verified date: March 2014
• Source: Technolas Perfect Vision GmbH
• Contact: n/a
• Is FDA regulated: No
• Health authority: Czech Republic: Ethics CommitteeIndia: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

This clinical study is a randomized, controlled, open, prospective, multi-centre, multi-surgeon post-market-clinical-follow-up study to investigate the impact of cataract grade on the efficacy and safety of femtosecond laser assisted lens fragmentation to support phacoemulsification of the cataractous lens prior to intraocular lens (IOL) implantation.

Description:

The purpose of the multi-centre, multi-surgeon, randomized, controlled, prospective, post-market-clinical-follow-up study clinical study is to investigate the impact of cataract grade on the safety and efficacy of femtosecond laser assisted lens fragmentation for cataract surgery by using VICTUS femtosecond laser platform.

In this study patients with different cataract grades [judged by lens opacity classification system (LOCS) III on nuclear opalescence) will be randomly assigned to either a manual group or a laser group, and aspects on efficacy and safety will be investigated.

• The sponsor and the investigators ensure, that all relevant documents are approved by their institutional review board / institutional ethics committee (IRB/IEC), or if not using their institution's IRB/IEC, approved by the reviewing central IRB/IEC prior to entering any subjects in the study.

• To avoid any potential bias during the process of patient assignment and in order to observe fair and true clinical significance a block randomization method will be employed and applied during the study.

• Subjects are regarded as enrolled to the clinical trial population as soon as they have signed and received the patient informed consent form (ICF) and underwent preoperative examinations.

• The sponsor's clinical group will accompany and monitor this study in respect to patient enrolment, eligibility control, randomization process, postoperative monitoring and data collection in accordance with the applicable regulations and the specifications required by the sponsor.

• All medical information obtained at each study visit will be recorded in the subject's record (source documentation) in real time as it is collected and then transcribed onto the case report form (CRF) by site personnel.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 136
• Est. completion date: February 2014
• Est. primary completion date: February 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Patients must have read, understood and signed the Patient Information

• Patients are willing and able to return for follow-up examinations

• Clear corneal media

• Cataract grade (nuclear) from I to V according to LOCS III

• Patients must be at least 40 years of age

Exclusion Criteria:

• Patients presenting a clear lens (clear lens exchange)

• Glaucoma and suspected glaucoma

• Patients with pre-existing proliferative diabetic retinopathy (mild and tight controlled diabetes symptoms, without retinopathy and non-proliferative diabetic retinopathy, can be included.)

• Retinal disorders

• Rheumatic diseases

• Occlusion of retinal vessels

• Pellucid marginal degeneration

• Herpes zoster or herpes simplex keratitis

• Heavy vascularization of the ocular tissue

• Epilepsy

• Recurrent corneal erosion

• Severe basement membrane disease

• Patients who suffer from severe wound-healing disorders such as connective tissue disease, autoimmune illnesses, immunodeficiency illnesses,endocrine diseases, lupus, rheumatoid arthritis, collagenosis, or clinically significant atopy

• Patients suffering from AIDS or HIV.

• Chemosis

• Significant loss of stability of the conjunctiva

• Nystagmus

• On a keratometric map of the cornea, the minimum and maximum K-values of the central 3 mm zone must not differ by more than 5 D.

• The maximum K-values must not exceed 60 D. The minimum value must not be smaller than 37 D.

• Patients who are pregnant or nursing.

• Patients who are blind in the fellow eye.

• Known sensitivity to planned concomitant medications.

• Patients with a recurrent or active ocular or uncontrolled eyelid disease.

• Subjects with a poorly dilating pupil.

• Patients with an anterior chamber depth (ACD) < 1.5 mm or ACD > 4.8 mm

• Presence of blood or other material in the anterior chamber.

• A history of lens instability (eg. posterior polar cataract, traumatic cataract) or zonular instability

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cataract

Intervention

Device:
• Femtosecond laser cataract surgery
The VICTUS lens fragmentation procedure is part of the femtosecond laser assisted cataract procedure, which generates precise cuts inside the cataractous lens, leading to a softening and fragmentation of the lens. The correct positioning of the cuts inside the lens can be verified by means of an optical coherence tomograph (OCT) before starting the laser assisted fragmentation process. Various surgical patterns will be used within this study. For each pattern different geometry/laser parameters can be adjusted individually according to each patient's cataract status. All the patients who are enrolled in the laser groups (all cataract grades) will be treated with femtosecond laser assisted capsulotomy before the femtosecond laser assisted lens fragmentation by VICTUS femtosecond laser platform.

Procedure:
• Manual cataract surgery
"Manual": manual group acts as a control group where the lens fragmentation are per-formed manually without femtosecond laser assisted lens fragmentation

Locations

Country	Name	City	State
Czech Republic	Gemini Eye Clinic	Zlin
India	MaxiVision Laser Centre Private Limited	Hyderabad

Sponsors (1)

Lead Sponsor	Collaborator
Technolas Perfect Vision GmbH

Countries where clinical trial is conducted

Czech Republic,  India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effective Phacoemulsification Time	The effective phacoemulsification time (EPT) used the "Laser group" (pooled from all grades) during phacoemulsification is lower than or equal to that in the "Manual group" (pooled from all grades); p<0.05 will be considered statistically significant.	This criterion should be achieved at the day of treatment.	No
Secondary	Adverse Events	Less or equal adverse events (e.g. retinal detachment, IOL malposition, etc.) in "Laser group" (pooled from all cataract grades) compared with "Manual group" (pooled from all cataract grades); p<0.05 will be considered statistically significant. The secondary study end point is only based on adverse events and severe adverse events which are related to the treatment procedures.	This purpose criterion should be achieved intraoperative, at 1 day, 1 week and 1 month.	Yes